Search

Zirconium chloride hydroxide

Eucalyptol

Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro. … Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition.

Stannous chloride

Stannous chloride is used as a source of tin in radiopharmaceutical kits. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].

Carprofen

Carprofen was previously used in human medicine for over 10 years (1985-1995). … It is no longer marketed for human usage, after being withdrawn on commercial grounds.

Apremilast

[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and

Testosterone enanthate

Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. … [A31615] This testosterone derivative was first approved on December 24, 1953.[L8941] In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659].

Liotrix

In fact, administration of T3 may result in supratherapeutic levels of T3. … It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues.

Alectinib

Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.

Angiotensin II

As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment … The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.

Danicopan

[eculizumab], [ravulizumab]) which are effective in mitigating complement-mediated intravascular hemolysis and thromboembolism. … [A263506] It was subsequently approved by the FDA in March 2024.[L50386]